 | Part 1: IntroductionDr Jonathan Rosenberg provides an overview of the staging and management of bladder cancer. He introduces the experts, Dr Joaquim Bellmunt and Dr Arlene Siefker-Radtke, and outlines the discussion topics. 03:27 min |
 | Part 2: ImmunotherapyDr Bellmunt summarizes data presented at ASCO-GU on immunotherapies for urothelial cancer. The experts discuss long-term outcomes with immunotherapy and the role of combination therapies. 14:08 min |
 | Part 3: Prognostic FactorsDr Rosenberg summarizes data presented at ASCO-GU on prognostic factors for immunotherapy outcomes. The experts discuss the relevance and utility of these factors for and in clinical practice. 12:16 min |
 | Part 4: Targeted TherapiesDr Siefker-Radtke summarizes data presented at ASCO-GU on therapies targeting the FGFR pathway. The experts discuss the management of patients with FGFR-altered tumors. 12:49 min |
 | Part 5: Final DiscussionThe experts discuss the highlights from ASCO-GU 2018 on the management of patients with bladder cancer; they also provide their outlook on developments in the neoadjuvant setting and on the increasing importance of biomarkers for personalized treatment approaches. 08:33 min |
